KRYS
Income statement / Annual
Last year (2024), Krystal Biotech, Inc.'s total revenue was $290.52 M,
an increase of 473.02% from the previous year.
In 2024, Krystal Biotech, Inc.'s net income was $89.16 M.
See Krystal Biotech, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$290.52 M |
$50.70 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.03 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$20.06 M
|
$3.09 M
|
$4.06 M
|
$2.77 M
|
$1.85 M
|
$974,000.00
|
$141,000.00
|
$23,000.00
|
$2,000.00
|
| Gross Profit |
$270.45 M
|
$47.61 M
|
-$4.06 M
|
-$2.77 M
|
-$1.85 M
|
-$974,000.00
|
$886,000.00
|
-$23,000.00
|
-$2,000.00
|
| Gross Profit Ratio |
0.93
|
0.94
|
0
|
0
|
0
|
0
|
0.86
|
0
|
0
|
| Research and Development Expenses |
$53.57 M
|
$46.43 M
|
$42.46 M
|
$27.88 M
|
$17.94 M
|
$15.62 M
|
$7.76 M
|
$3.21 M
|
$741,000.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$77.74 M
|
$40.39 M
|
$15.06 M
|
$6.47 M
|
$4.16 M
|
$1.56 M
|
$402,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$113.69 M
|
$98.40 M
|
$77.74 M
|
$40.39 M
|
$15.06 M
|
$6.47 M
|
$4.16 M
|
$1.56 M
|
$402,000.00
|
| Other Expenses |
$37.50 M
|
$12.50 M
|
$25.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$204.76 M
|
$157.33 M
|
$120.20 M
|
$68.28 M
|
$33.00 M
|
$22.08 M
|
$11.92 M
|
$4.77 M
|
$1.14 M
|
| Cost And Expenses |
$224.82 M
|
$147.93 M
|
$120.20 M
|
$68.28 M
|
$33.00 M
|
$22.08 M
|
$11.92 M
|
$4.77 M
|
$1.14 M
|
| Interest Income |
$29.66 M
|
$22.62 M
|
$5.22 M
|
$197,000.00
|
$832,000.00
|
$2.99 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$5.22 M
|
$1.49 M
|
$0.00
|
$0.00
|
$1.03 M
|
$3.15 M
|
$7,000.00
|
| Depreciation & Amortization |
$6.75 M
|
$5.01 M
|
$4.06 M
|
$2.77 M
|
$1.85 M
|
$974,000.00
|
$141,000.00
|
$23,000.00
|
$2,000.00
|
| EBITDA |
$109.91 M |
$17.90 M |
-$145.20 M |
-$65.31 M |
-$30.32 M |
-$18.11 M |
-$10.75 M |
-$4.63 M |
-$1.14 M |
| EBITDA Ratio |
0.38
|
0.35
|
0
|
0
|
0
|
0
|
-10.47
|
0
|
0
|
| Operating Income Ratio |
0.23
|
-2.16
|
0
|
0
|
0
|
0
|
-11.6
|
0
|
0
|
| Total Other Income/Expenses Net |
$29.66 M
|
$122.62 M
|
$5.22 M
|
-$1.30 M
|
$832,000.00
|
$2.99 M
|
$1.03 M
|
-$3.15 M
|
-$7,000.00
|
| Income Before Tax |
$95.36 M
|
$12.90 M
|
-$139.98 M
|
-$69.57 M
|
-$32.17 M
|
-$19.09 M
|
-$10.89 M
|
-$7.92 M
|
-$1.15 M
|
| Income Before Tax Ratio |
0.33
|
0.25
|
0
|
0
|
0
|
0
|
-10.6
|
0
|
0
|
| Income Tax Expense |
$6.20 M
|
$1.97 M
|
$34.05 M
|
$2.73 M
|
$1.64 M
|
$576,140.00
|
-$20,141.00
|
$0.00
|
$0.00
|
| Net Income |
$89.16 M
|
$10.93 M
|
-$139.98 M
|
-$69.57 M
|
-$32.17 M
|
-$19.09 M
|
-$10.89 M
|
-$7.92 M
|
-$1.15 M
|
| Net Income Ratio |
0.31
|
0.22
|
0
|
0
|
0
|
0
|
-10.6
|
0
|
0
|
| EPS |
3.12 |
0.4 |
-5.49 |
-3.13 |
-1.71 |
-1.2 |
-0.97 |
-1.48 |
-0.27 |
| EPS Diluted |
3 |
0.39 |
-5.49 |
-3.13 |
-1.71 |
-1.2 |
-0.97 |
-1.48 |
-0.27 |
| Weighted Average Shares Out |
$28.59 M
|
$27.15 M
|
$25.49 M
|
$22.20 M
|
$18.79 M
|
$15.90 M
|
$11.20 M
|
$5.36 M
|
$4.28 M
|
| Weighted Average Shares Out Diluted |
$29.74 M
|
$27.75 M
|
$25.49 M
|
$22.20 M
|
$18.79 M
|
$15.90 M
|
$11.20 M
|
$5.36 M
|
$4.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
